This review synthesizes the utility of exhaled volatile organic compounds (VOCs) in cancer diagnosis, treatment efficacy prediction, and recurrence monitoring. As endogenous metabolic byproducts, VOCs enable noninvasive detection via technologies like gas chromatography-mass

spectrometry (GC-MS), electronic noses, selected ion flow tube mass spectrometry (SIFT-MS), and high-pressure photonionization time-of-flight mass spectrometry (HPPI-TOFMS).

Key findings include strong diagnostic performance (e.g., lung cancer AUC=0.95, hepatocellular carcinoma VOC sensitivity outperforming AFP)，accurate prediction of anti-PD-1/PD-L1 therapy response (AUC=0.89–0.97), and utility in colorectal cancer postoperative recurrence surveillance. Innovatively, it links VOC alterations to mechanisms (oxidative stress, CYP450 overexpression) and compares detection technologies’ strengths/limitations.

Clinical implications: VOCs address gaps of traditional biomarkers (low sensitivity/specificity)， while highlighting needs for standardized sampling/analysis protocols and improved device stability to advance clinical translation.

Most scientific data never fuel the discoveries they should. 

For every 100 datasets created, around 80 remain in the lab, 20 are shared but rarely reused, fewer than two meet FAIR standards, and only one typically drives new findings. 

The result: delayed cancer treatments, climate models short on evidence, and research that cannot be reproduced. 

Frontiers, the open-science publisher, is tackling this problem with the launch of Frontiers FAIR² Data Management, the world’s first all-in-one, AI-powered service for research data. Designed to transform how data is shared so it is reusable and credited, it brings together curation, compliance checks, AI-ready packaging, peer review, an interactive portal, certification, and lifetime hosting in a single workflow — ensuring that research funded today delivers faster breakthroughs in health, sustainability, and technology tomorrow.

The latest research advances and scientific discoveries in otolaryngology-head and neck surgery were presented during the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting & OTO EXPO. From hundreds of research presentations submitted, the Annual Meeting Program Committee selected 19 exceptional studies as the "Best of Scientific Oral Presentations," recognizing their potential to further patient care and advance the field.

This review addresses cancer therapy limitations (systemic toxicity, multidrug resistance, MDR) via innovative nanoparticle (NP) platforms. Innovations include dual-phase liposomes (co-deliver hydrophilic/hydrophobic drugs, e.g., HA-functionalized ones for CD44⁺ brain tumors), green-synthesized metal NPs (low toxicity), MOF NPs (induce pyroptosis to boost immunity), and cell membrane-coated NPs (avoid RES clearance). It combines passive (EPR effect) and active (ligand-receptor) targeting.

Clinically, NPs reduce toxicity, enable delivery to hard-to-reach sites (e.g., brain), and overcome MDR. While long-term safety needs validation, NPs offer promise for personalized, less toxic oncology care.